Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2015-02-12 | 3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethylcarbamoyl)-pyridine-2-carboxylic acid | BioCryst Pharmaceuticals (USA - NC) BioCryst UK | hereditary angioedema |
Granting of the orphan status in the EU |
2015-02-12 | fibrinogen-coated albumin spheres | Fibreu Limited (UK) | Ebola fever |
Granting of the orphan status in the EU |
2015-02-12 | nitroglycerin | Covis Pharma (USA - NC) Covis Pharma, S.à.r.l. (Switzerland) | systemic sclerosis |
Granting of the orphan status in the EU |
2015-03-17 | sevuparin sodium | Dilaforette (Sweden) | sickle cell disease |
Granting of the orphan status in the US |
2015-02-15 | 2'-O-methyl phosphorothioate RNA oligonucleotide, 5'-m5CUGm5CUGm5CUGm5CUGm5CUGm5CUGm5CUG-3' | Prosensa (The Netherlands) now BioMarin Pharmaceutical (USA - CA) | Huntington's disease |
Granting of the orphan status in the EU |
2015-02-12 | 5-hydroxymethyl-2-furfural | Baxter (USA - IL) | sickle cell disease |
Granting of the orphan status in the EU |
2015-01-09 | allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus | Miltenyi Biotec (Germany) | cytomegalovirus infection following haematopoietic stem cell transplantation |
Granting of the orphan status in the EU |
2015-03-19 | allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus | Miltenyi Biotec (Germany) | adenovirus infection following haematopoietic stem cell transplantation |
Granting of the orphan status in the EU |
2015-03-19 | allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus | Miltenyi Biotec (Germany) | Epstein-Barr virus infection following haematopoietic stem cell transplantation |
Granting of the orphan status in the EU |
2015-02-12 | alvocidib | Theorem Clinical Research (USA - PA) Tolero Pharmaceuticals (USA - UT) | acute myeloid leukaemia |
Granting of the orphan status in the EU |
2015-02-12 | Lactobacillus reuteri | Infant Bacterial Therapeutics (Sweden) | prevention of necrotising enterocolitis |
Granting of the orphan status in the EU |
2015-02-12 | mazindol | HAC Pharma (France) | narcolepsy |
Granting of the orphan status in the EU |
2015-02-12 | myriocin | Nanovector (Italy) | retinitis pigmentosa |
Granting of the orphan status in the EU |
2017-03-20 | N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulphate salt | AlzProtect (France) | progressive supranuclear palsy | Granting of the orphan status in the US |
2016-11-11 | olaratumab | Eli Lilly (USA - IN) | soft tissue sarcoma |
Granting of a Market Authorisation in the EU |
2015-02-12 | recombinant human glutamate oxaloacetate transaminase 1 | Impasara (UK) | glioma |
Granting of the orphan status in the EU |
2016-09-12 | etanercept biosimilar | Samsung Bioepis (Republic of Korea) Merck&Co (USA - NJ) | moderate-to-severe rheumatoid arthritis psoriatic arthritis non-radiographic axial spondyloarthritis plaque psoriasis |
Granting of a Market Authorisation in Canada |
2015-03-26 | lamivudine/raltegravir | Merck&Co (USA - NJ) | treatment of human immunodeficiency virus (HIV 1) infection in adults, adolescents, and children from the age of 6 years and weighing at least 30 kg |
Granting of a Market Authorisation in the EU |
2015-03-19 | ciclosporin | Santen SAS (France) | severe keratitis in adult patients with dry eye disease | Granting of a Market Authorisation in the EU |
2015-04-30 | mixture of fibrinogen and thrombin | The Medicines Company (USA - NJ) - ProFibrix (The Netherlands) | supportive treatment to help control bleeding during surgery |
Granting of a Market Authorisation in the US |
© 2024 Biopharmanalyses - Powered by Samacom+